Henlius Delivers On Innovation Agenda In 2021
Revenue At The Chinese Firm Has Increased By 186.3% Year On Year
Henlius has focused its efforts on becoming a fully-fledged biopharmaceutical company during 2021, moving away from its roots as a biosimilar drug company.
